Cerdulatinib, a dual SYK/JAK-STAT inhibitor, targets BCR signaling and is also able to overcome microenvironmental protection and blocks proliferation in ibrutinib-resistant primary CLL samples and BTKC481S lymphoma cell lines (Figure 1) (133). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.